NCT/Study#

CDA024-2021

Phase 1b/2, open-label dose escalation with expansion study of a ACTIVE investigational product in adult subjects with relapsed/refractory primary or secondary central nervous system lymphoma, followed by a Phase 2 open-label single dose level study of the study drug in adult subjects with relapsed/refractory primary central nervous system lymphoma.

Phase 1b/2, open-label dose escalation with expansion study of a ACTIVE investigational product in adult subjects with relapsed/refractory primary or secondary central nervous system lymphoma, followed by a Phase 2 open-label single dose level study of the study drug in adult subjects with relapsed/refractory primary central nervous system lymphoma.

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: